Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia

International Journal of Urology

Volumn 17, Issue 10, 2010, Pages 869-875

  Miyakita, Hideshi ^a   Yokoyama, Eiji ^b   Onodera, Yasutada ^c   Utsunomiya, Takuji ^d   Tokunaga, Masatoshi ^a   Tojo, Takanori ^e   Fujii, Noriteru ^f   Yanada, Shuichi ^g  

^a TOKAI UNIVERSITY OISO HOSPITAL   (Japan)

^b Yokoyama Medical Clinic   (Japan)

^c Onodera Clinic   (Japan)

^d Atsugi City Hospital   (Japan)

^e Morishita Memorial Hospital   (Japan)

^f Chuo Rinkan Hospital   (Japan)

^g Hiratsuka Kyosai Hospital   (Japan)

Author keywords

benign prostatic hyperplasia; crossover treatment; lower urinary tract symptoms; silodosin; tamsulosin hydrochloride

Indexed keywords

SILODOSIN; TAMSULOSIN;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EJACULATION DISORDER; GAIT DISORDER; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; NOCTURIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMACH DISCOMFORT; URINARY FREQUENCY; URINARY URGENCY;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; CROSS-OVER STUDIES; HUMANS; INDOLES; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SULFONAMIDES; TREATMENT OUTCOME; URINARY TRACT; URINATION DISORDERS;

EID: 77957285079     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02614.x     Document Type: Article

References (22)

1. Study Group on the Standardization of Treatment in the Field of Urology. Guidelines for Treatment of Benign Prostatic Hyperplasia Based on EBM. Jiho
2. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J. Urol. 2003 170 : 530 47.
3. Marshall I, Burt RP, Chapple CR. Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype. Br. J. Pharmacol. 1995 115 : 781 6.
4. Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, Takeda M. Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br. J. Pharmacol. 1994 113 : 723 8. (Pubitemid 24326807)
5. Murata S, Taniguchi T, Takahashi M, Okada K, Akiyama K, Muramatsu I. Tissue selectivity of KMD-3213, an alpha(1)-adrenoceptor antagonist, in human prostate and vasculature. J. Urol. 2000 164 : 578 83. (Pubitemid 30481987)
6. Schwinn DA. Novel role for alpha1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int. 2000 86 : 11 20.
7. Kaplan SA. Alpha-Blocker therapy: current update. Rev. Urol. 2005 7 : S34 42.
8. Chapple C, Andersson KE. Tamsulosin: an overview. World J. Urol. 2002 19 : 397 404.
9. Shibata K, Foglar R, Horie K et al. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol. Pharmacol. 1995 48 : 250 8.
10. Tatemichi S, Kobayashi K, Maezawa A, Kobayashi M, Yamazaki Y, Shibata N. Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi 2006 126 : 209 16.
11. Akiyama K, Hora M, Tatemichi S et al. KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model. J. Pharmacol. Exp. Ther. 1999 291 : 81 91. (Pubitemid 29451576)
12. Tatemichi S, Tomiyama Y, Maruyama I et al. Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia. Neurourol. Urodyn. 2006 25 : 792 9. (Pubitemid 44691386)
13. Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1A-adrenoceptor- selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006 98 : 1019 24. (Pubitemid 44536452)
14. Yoshida M, Homma Y, Kawabe K. Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin. Investig. Drugs 2007 16 : 1955 65. (Pubitemid 351403726)
15. Yokoyama O, Takada A, Matsushima H, Imoto M. Bioequivalence Study of Tamsulosin Hydrochloride 0.2 mg Oral Disintegrating Tablets (WOWTAB) and 0.2 mg Capsules in Human Under the Fed Condition. Jpn, Pharmacol. Ther. 2005 33 : 521 6. (Pubitemid 41261870)
16. Homma Y, Yamaguchi O, Hayashi K. Epidemiologic survey of lower urinary tract symptoms in Japan. Urology 2006 68 : 560 4. (Pubitemid 44436493)
17. Yoshimura K, Arai Y, Ichioka K, Terada N, Matsuta Y, Okubo K. Symptom-specific quality of life in patients with benign prostatic hyperplasia. Int. J. Urol. 2002 9 : 485 90. (Pubitemid 35365566)
18. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J. Urol. 2009 181 : 2634 40.
19. Kobayashi K, Masumori N, Hisasue S et al. Inhibition of seminal emission is the main cause of an ejaculation induced by a new highly selective alpha1A-blocker in normal volunteers. J. Sex. Med. 2008 5 : 2185 90.
20. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998 51 : 892 900. (Pubitemid 28240845)
21. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J. Urol. 1998 160 : 1701 6. (Pubitemid 128746741)
22. Höfner K, Claes H, De Reijke TM, Folkestad B, Speakman MJ. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur. Urol. 1999 36 : 335 41. (Pubitemid 29419452)